Evidence map›Paper›PMID 27145134›Full record

ArticleMolecular microbiology2016

A scaffold protein connects type IV pili with the Chp chemosensory system to mediate activation of virulence signaling in Pseudomonas aeruginosa.

Yuki F Inclan, Alexandre Persat, Alexander Greninger, John Von Dollen, Jeffery Johnson, Nevan Krogan, Zemer Gitai, Joanne N Engel

Open access · greenAbstract read
In one paragraph

Article in Molecular microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 94 citations in OpenAlex.

  1. Article
  2. Distinct roles of PilI and ChpC inApplied and environmental microbiology · 2026
    Article
  3. Article
  4. A farnesol-sensing triad inProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  5. Review
  6. Article
  7. Transcriptional profiling ofFrontiers in microbiology · 2026
    Article
  8. Review
  9. Separation ofmBio · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. ThemSphere · 2024
    Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Yuki F InclanDepartment of Medicine, University of California, San Francisco, San Francisco, CA, 94143, USA.
Alexandre PersatDepartment of Biology, Princeton University, Princeton, NJ, 08544, USA.
Alexander GreningerDepartment of Biochemistry, University of California, San Francisco, San Francisco, CA, 94143, USA.
John Von DollenCalifornia Institute for Quantitative Biosciences, San Francisco, CA, 94148, USA.
Jeffery JohnsonCalifornia Institute for Quantitative Biosciences, San Francisco, CA, 94148, USA.
Nevan KroganCalifornia Institute for Quantitative Biosciences, San Francisco, CA, 94148, USA.
Zemer GitaiDepartment of Biology, Princeton University, Princeton, NJ, 08544, USA.
Joanne N EngelDepartment of Medicine, University of California, San Francisco, San Francisco, CA, 94143, USA.
University of California, San Francisco · USPrinceton University · USGladstone Institutes · US

Funding

Microbial Pathogenesis and Host DefenseT32AI060537 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joanne N. Engel · 2004 to 2026
$6.5M
MECHANISM OF PSEUDOMONAS MEDIATED EPITHELIAL CELL DAMAGER01AI042806 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ENGEL, JOANNE N. · 1998 to 2010
$4.6M
Mechano-microbiology: how physical forces control bacterial-host interactionsDP1AI124669 · NIAID · PRINCETON UNIVERSITY · PI GITAI, ZEMER · 2015 to 2019
$4.0M
New approaches to study Pseudomonas-host interactionsR56AI065902 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ENGEL, JOANNE N. · 2015 to 2015
$396k
NIAID NIH HHS DP1 AI124669NIAID NIH HHS R01 AI042806NIAID NIH HHS R56 AI065902NIAID NIH HHS T32 AI060537
6 · The paper itself

Abstract

Type IV pili (TFP) function as mechanosensors to trigger acute virulence programs in Pseudomonas aeruginosa. On surface contact, TFP retraction activates the Chp chemosensory system phosphorelay to upregulate 3', 5'-cyclic monophosphate (cAMP) production and transcription of virulence-associated genes. To dissect the specific interactions mediating the mechanochemical relay, we used affinity purification/mass spectrometry, directed co-immunoprecipitations in P. aeruginosa, single cell analysis of contact-dependent transcriptional reporters, subcellular localization and bacterial two hybrid assays. We demonstrate that FimL, a Chp chemosensory system accessory protein of unknown function, directly links the integral component of the TFP structural complex FimV, a peptidoglycan binding protein, with one of the Chp system output response regulators PilG. FimL and PilG colocalize at cell poles in a FimV-dependent manner. While PilG phosphorylation is required for TFP function and mechanochemical signaling, it is not required for polar localization or binding to FimL. Phylogenetic analysis reveals other bacterial species simultaneously encode TFP, the Chp system, FimL, FimV and adenylate cyclase homologs, suggesting that surface sensing may be widespread among TFP-expressing bacteria. We propose that FimL acts as a scaffold enabling spatial colocalization of TFP and Chp system components to coordinate signaling leading to cAMP-dependent upregulation of virulence genes on surface contact.

Indexed as

Adenylyl CyclasesCyclic AMPFimbriae, BacterialFimbriae ProteinsPeptidoglycanPhylogenyPseudomonas aeruginosaSignal TransductionVirulenceAdenylyl CyclasesCyclic AMPFimbriae ProteinsPeptidoglycan

Identifiers

PMID27145134
PMCPMC4980298
OpenAlexW2368412265

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.